

FOR IMMEDIATE RELEASE
December 1, 2015

Eisai Co., Ltd.
Toyama Chemical Co., Ltd.

**EISAI AND TOYAMA CHEMICAL CLEAR ALL-CASE SURVEILLANCE CONDITION
FOR APPROVAL OF ANTIRHEUMATIC AGENT IGURATIMOD
(BRAND NAMES: CARERAM[®] TABLETS 25 MG/KOLBET[®] TABLETS 25 MG)**

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Fujifilm Group company Toyama Chemical Co., Ltd. (Headquarters: Tokyo, President: Masuji Sugata, "Toyama Chemical") announced today that they have received notification from Japan's Ministry of Health, Labour and Welfare (MHLW) to the effect that the "all-case surveillance" special drug use-results survey

iguratimod indicated for rheumatoid arthritis with the following
of iguratimod, the use-results survey should be conducted
until adequate data from a certain number of cases have
the background of those patients, and efficacy and safety
after marketing of the product so that actions necessary for
Eisai and Toyama Chemical jointly conducted an all-case
who had been treated with iguratimod between launch on
and submitted the results of an interim analysis on the first
nts to the MHLW. Based on the safety and efficacy data
on for approval after determining that there are no issues
proper use of the product.

iguratimod is a disease-modifying antirheumatic drug (DMARD)
agent in Japan to demonstrate efficacy in domestic clinical
methotrexate (MTX), the standard of care, in rheumatoid arthritis
any benefit with MTX alone. As an antirheumatic drug, it is
new option for drug therapy of rheumatoid arthritis and
choose a drug therapy regime that matches their condition.
joint development of the agent in Japan based on a
that previously concluded between the two companies. After
Toyama Pharmaceutical Co., Ltd. launched iguratimod under

[®] Tablets 25 mg and KOLBET[®] Tablets 25 mg, respectively, with each company working to market their product and provide information on its proper use.

Eisai and Toyama Chemical will continue to promote and provide information on the proper use of iguratimod while making further contributions to improve the quality of life of patients.

Media Inquiries	
Public Relations Department Eisai Co., Ltd. +81-(0)3-3817-5120	General Affairs Group, General Affairs and Personnel Department Toyama Chemical Co., Ltd. +81-(0)3-5381-3818

